JP Morgan Chase
FOLD

JP Morgan Chase’s Amicus Therapeutics FOLD Stock Holding History

JP Morgan Chase’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$97.4M Buy
6,749,190
+3,031,827
+82% +$43.5M 0.01% 998
2025
Q4 		$52.9M Buy
3,717,363
+1,601,197
+76% +$15.7M ﹤0.01% 1331
2025
Q3 		$16.7M Sell
2,116,166
-94,105
-4% -$670K ﹤0.01% 2253
2025
Q2 		$12.7M Sell
2,210,271
-2,684,013
-55% -$17.3M ﹤0.01% 2342
2025
Q1 		$39.9M Sell
4,894,284
-2,319,966
-32% -$21.5M ﹤0.01% 1443
2024
Q4 		$68M Sell
7,214,250
-5,705,679
-44% -$59.3M 0.01% 1135
2024
Q3 		$138M Sell
12,919,929
-1,950,851
-13% -$21.2M 0.01% 828
2024
Q2 		$148M Sell
14,870,780
-820,377
-5% -$8.42M 0.01% 760
2024
Q1 		$185M Sell
15,691,157
-2,157,374
-12% -$27.6M 0.02% 676
2023
Q4 		$253M Buy
17,848,531
+4,839,102
+37% +$54.9M 0.02% 548
2023
Q3 		$158M Sell
13,009,429
-432,962
-3% -$5.59M 0.02% 628
2023
Q2 		$169M Sell
13,442,391
-291,094
-2% -$3.45M 0.02% 619
2023
Q1 		$152M Buy
13,733,485
+186,117
+1% +$2.29M 0.02% 631
2022
Q4 		$165M Sell
13,547,368
-790,337
-6% -$8.9M 0.02% 579
2022
Q3 		$150M Sell
14,337,705
-1,526,402
-10% -$17M 0.02% 577
2022
Q2 		$170M Buy
15,864,107
+312,291
+2% +$2.57M 0.02% 558
2022
Q1 		$147M Buy
15,551,816
+207,988
+1% +$1.95M 0.02% 679
2021
Q4 		$177M Buy
15,343,828
+60,770
+0.4% +$677K 0.02% 616
2021
Q3 		$146M Buy
15,283,058
+1,996,622
+15% +$20.4M 0.02% 690
2021
Q2 		$128M Buy
13,286,436
+1,406,612
+12% +$13.7M 0.02% 782
2021
Q1 		$117M Buy
11,879,824
+3,420,907
+40% +$53M 0.02% 775
2020
Q4 		$195M Buy
8,458,917
+158,151
+2% +$3.23M 0.03% 537
2020
Q3 		$117M Buy
8,300,766
+257,075
+3% +$3.75M 0.02% 646
2020
Q2 		$121M Buy
8,043,691
+1,379,685
+21% +$16.8M 0.02% 587
2020
Q1 		$61.6M Buy
6,664,006
+2,767,576
+71% +$26.3M 0.01% 726
2019
Q4 		$38M Buy
3,896,430
+2,989,745
+330% +$27.4M 0.01% 1120
2019
Q3 		$7.27M Buy
906,685
+46,066
+5% +$500K ﹤0.01% 2381
2019
Q2 		$10.3M Sell
860,619
-23,488
-3% -$298K ﹤0.01% 2085
2019
Q1 		$12M Sell
884,107
-11,973
-1% -$146K ﹤0.01% 1888
2018
Q4 		$8.58M Sell
896,080
-80,376
-8% -$884K ﹤0.01% 2146
2018
Q3 		$11.8M Buy
976,456
+47,411
+5% +$663K ﹤0.01% 2060
2018
Q2 		$14.5M Sell
929,045
-54,978
-6% -$831K ﹤0.01% 1846
2018
Q1 		$14.8M Sell
984,023
-6,337
-0.6% -$96.4K ﹤0.01% 1741
2017
Q4 		$14.3M Sell
990,360
-271,640
-22% -$3.73M ﹤0.01% 1845
2017
Q3 		$18.6M Sell
1,262,000
-19,633
-2% -$260K ﹤0.01% 1554
2017
Q2 		$12.9M Sell
1,281,633
-184,281
-13% -$1.48M ﹤0.01% 1772
2017
Q1 		$10.5M Buy
1,465,914
+44,828
+3% +$283K ﹤0.01% 1903
2016
Q4 		$7.06M Buy
1,421,086
+967,235
+213% +$6.69M ﹤0.01% 2171
2016
Q3 		$3.36M Sell
453,851
-538,838
-54% -$3.64M ﹤0.01% 2497
2016
Q2 		$5.42M Sell
992,689
-145,653
-13% -$1.02M ﹤0.01% 2232
2016
Q1 		$9.62M Buy
1,138,342
+223,543
+24% +$1.58M ﹤0.01% 1797
2015
Q4 		$8.87M Buy
914,799
+481,760
+111% +$4.34M ﹤0.01% 1891
2015
Q3 		$6.06M Buy
+433,039
New +$6.79M ﹤0.01% 2102
2015
Q2 		– Sell
-253,449
Closed -$2.76M – 4066
2015
Q1 		$2.76M Buy
+253,449
New +$2.23M ﹤0.01% 2709
2013
Q3 		– Sell
-271,811
Closed -$634K – 4402
2013
Q2 		$634K Buy
+271,811
New +$835K ﹤0.01% 3487

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

JP Morgan Chase's FOLD Position: Q1 2026 in Review

JP Morgan Chase increased its Amicus Therapeutics (FOLD) stake by 82% in Q1 2026, buying an estimated $43.5M and bringing the position to 6,749,190 shares worth $97.4M. The position accounts for 0.01% of the portfolio, ranked #998.

JP Morgan Chase first reported a position in FOLD in Q2 2013 and has held it in 45 quarters since. The position peaked at $253M in Q4 2023. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • JP Morgan Chase held 6,749,190 shares of Amicus Therapeutics worth $97.4M as of Q1 2026.
  • JP Morgan Chase bought 3,031,827 Amicus Therapeutics shares in Q1 2026, an estimated $43.5M.
  • Amicus Therapeutics made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #998 holding.
  • JP Morgan Chase first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 45 quarters since.
  • JP Morgan Chase's Amicus Therapeutics position peaked at $253M in Q4 2023.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.